Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston, Texas, USA.
Department of Leukemia, MD Anderson Cancer Center, Houston, Texas, USA.
Oncologist. 2019 Jun;24(6):772-782. doi: 10.1634/theoncologist.2018-0257. Epub 2018 Nov 16.
Rapid advances in science challenge the timely adoption of evidence-based care in community settings. To bridge the gap between what is possible and what is practiced, we researched approaches to developing an artificial intelligence (AI) application that can provide real-time patient-specific decision support.
The Oncology Expert Advisor (OEA) was designed to simulate peer-to-peer consultation with three core functions: patient history summarization, treatment options recommendation, and management advisory. Machine-learning algorithms were trained to construct a dynamic summary of patients cancer history and to suggest approved therapy or investigative trial options. All patient data used were retrospectively accrued. Ground truth was established for approximately 1,000 unique patients. The full Medline database of more than 23 million published abstracts was used as the literature corpus.
OEA's accuracies of searching disparate sources within electronic medical records to extract complex clinical concepts from unstructured text documents varied, with F1 scores of 90%-96% for non-time-dependent concepts (e.g., diagnosis) and F1 scores of 63%-65% for time-dependent concepts (e.g., therapy history timeline). Based on constructed patient profiles, OEA suggests approved therapy options linked to supporting evidence (99.9% recall; 88% precision), and screens for eligible clinical trials on ClinicalTrials.gov (97.9% recall; 96.9% precision).
Our results demonstrated technical feasibility of an AI-powered application to construct longitudinal patient profiles in context and to suggest evidence-based treatment and trial options. Our experience highlighted the necessity of collaboration across clinical and AI domains, and the requirement of clinical expertise throughout the process, from design to training to testing.
Artificial intelligence (AI)-powered digital advisors such as the Oncology Expert Advisor have the potential to augment the capacity and update the knowledge base of practicing oncologists. By constructing dynamic patient profiles from disparate data sources and organizing and vetting vast literature for relevance to a specific patient, such AI applications could empower oncologists to consider all therapy options based on the latest scientific evidence for their patients, and help them spend less time on information "hunting and gathering" and more time with the patients. However, realization of this will require not only AI technology maturation but also active participation and leadership by clincial experts.
科学的快速进步挑战了在社区环境中及时采用基于证据的护理。为了弥合可能与实践之间的差距,我们研究了开发人工智能 (AI) 应用程序的方法,该应用程序可以提供实时的患者特定决策支持。
肿瘤学专家顾问 (OEA) 旨在模拟同行咨询,具有三个核心功能:患者病史总结、治疗方案推荐和管理建议。机器学习算法经过训练,可以构建患者癌症病史的动态摘要,并建议批准的治疗或研究性试验方案。使用的所有患者数据均为回顾性收集。为大约 1000 名独特患者建立了真实基准。使用包含超过 2300 万篇已发表摘要的完整 Medline 数据库作为文献语料库。
OEA 从非结构化文本文档中提取电子病历中不同来源的复杂临床概念的搜索准确率各不相同,非时间依赖概念(例如诊断)的 F1 分数为 90%-96%,时间依赖概念(例如治疗史时间轴)的 F1 分数为 63%-65%。根据构建的患者资料,OEA 会根据支持证据建议批准的治疗方案(召回率 99.9%;精度 88%),并在 ClinicalTrials.gov 上筛选合格的临床试验(召回率 97.9%;精度 96.9%)。
我们的研究结果证明了基于人工智能的应用程序构建上下文相关的纵向患者资料并建议基于证据的治疗和试验方案的技术可行性。我们的经验强调了临床和人工智能领域之间合作的必要性,以及在从设计到培训再到测试的整个过程中需要临床专业知识。
肿瘤学专家顾问等人工智能 (AI) 驱动的数字顾问有可能增强执业肿瘤学家的能力并更新知识库。通过从不同数据源构建动态患者资料,并组织和审查与特定患者相关的大量文献,这种 AI 应用程序可以使肿瘤学家能够根据最新的科学证据为患者考虑所有治疗方案,并帮助他们减少在信息“搜索和收集”上的时间,而与患者在一起的时间更多。但是,要实现这一目标,不仅需要人工智能技术的成熟,还需要临床专家的积极参与和领导。